Literature DB >> 15748992

Lactobacillus casei DN-114 001 inhibits the increase in paracellular permeability of enteropathogenic Escherichia coli-infected T84 cells.

Nadège Parassol1, Miguel Freitas, Karine Thoreux, Guillaume Dalmasso, Raphaelle Bourdet-Sicard, Patrick Rampal.   

Abstract

Probiotics are living microorganisms which, when ingested in adequate amounts, exert health benefits toward the host. For instance, probiotics might act through reinforcement of the intestinal epithelial barrier function. The goal of the present study was to determine whether Lactobacillus casei DN-114 001 could abrogate the increase in paracellular permeability induced by enteropathogenic Escherichia coli. We used the human colon T84 cell line infected with a wild-type enteropathogenic E. coli (strain E2348/69). Paracellular permeability was followed by monitoring transepithelial electrical resistance variations and by observing zonula occludens-1 distribution. Two infection procedures were used: co-incubation (the pathogenic and probiotic strains were simultaneously incubated with T84 cells) and post-infection (the probiotic was added in the presence of pathogenic bacteria 3 h after the beginning of the infection). We also investigated the effect of L. casei on enteropathogenic E. coli adhesion. L. casei DN-114 001 inhibited, in a dose-dependent-manner, the decrease in enteropathogenic E. coli-induced transepithelial electrical resistance and zonula occludens-1 redistribution using two different infection procedures. However, L. casei did not inhibit pathogenic strain adhesion. L. casei DN-114 001 inhibited the increase in EPEC-induced paracellular permeability. This property could partially explain the previously observed health benefits of this probiotic for human natural defenses, such as those associated with prevention of diarrhea.

Entities:  

Mesh:

Year:  2004        PMID: 15748992     DOI: 10.1016/j.resmic.2004.09.013

Source DB:  PubMed          Journal:  Res Microbiol        ISSN: 0923-2508            Impact factor:   3.992


  44 in total

1.  Bifidobacterium bifidum improves intestinal integrity in a rat model of necrotizing enterocolitis.

Authors:  Ludmila Khailova; Katerina Dvorak; Kelly M Arganbright; Melissa D Halpern; Toshi Kinouchi; Masako Yajima; Bohuslav Dvorak
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2009-11       Impact factor: 4.052

Review 2.  The front line of enteric host defense against unwelcome intrusion of harmful microorganisms: mucins, antimicrobial peptides, and microbiota.

Authors:  Vanessa Liévin-Le Moal; Alain L Servin
Journal:  Clin Microbiol Rev       Date:  2006-04       Impact factor: 26.132

Review 3.  Gut-liver axis and probiotics: their role in non-alcoholic fatty liver disease.

Authors:  Giulia Paolella; Claudia Mandato; Luca Pierri; Marco Poeta; Martina Di Stasi; Pietro Vajro
Journal:  World J Gastroenterol       Date:  2014-11-14       Impact factor: 5.742

4.  Probiotic treatments for induction and maintenance of remission in inflammatory bowel diseases: a meta-analysis of randomized controlled trials.

Authors:  Mikihiro Fujiya; Nobuhiro Ueno; Yutaka Kohgo
Journal:  Clin J Gastroenterol       Date:  2013-12-28

Review 5.  A review of the pharmacobiotic regulation of gastrointestinal inflammation by probiotics, commensal bacteria and prebiotics.

Authors:  L Vitetta; D Briskey; E Hayes; C Shing; J Peake
Journal:  Inflammopharmacology       Date:  2012-03-18       Impact factor: 4.473

Review 6.  The role of the gastrointestinal tract and microbiota on uremic toxins and chronic kidney disease development.

Authors:  David Briskey; Patrick Tucker; David W Johnson; Jeff S Coombes
Journal:  Clin Exp Nephrol       Date:  2016-03-10       Impact factor: 2.801

7.  Protection and Restitution of Gut Barrier by Probiotics: Nutritional and Clinical Implications.

Authors:  R K Rao; G Samak
Journal:  Curr Nutr Food Sci       Date:  2013-05-01

8.  Use of a fermented dairy probiotic drink containing Lactobacillus casei (DN-114 001) to decrease the rate of illness in kids: the DRINK study. A patient-oriented, double-blind, cluster-randomized, placebo-controlled, clinical trial.

Authors:  D Merenstein; M Murphy; A Fokar; R K Hernandez; H Park; H Nsouli; M E Sanders; B A Davis; V Niborski; F Tondu; N M Shara
Journal:  Eur J Clin Nutr       Date:  2010-05-19       Impact factor: 4.016

9.  Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability.

Authors:  P D Cani; S Possemiers; T Van de Wiele; Y Guiot; A Everard; O Rottier; L Geurts; D Naslain; A Neyrinck; D M Lambert; G G Muccioli; N M Delzenne
Journal:  Gut       Date:  2009-02-24       Impact factor: 23.059

10.  L. plantarum prevents enteroinvasive Escherichia coli-induced tight junction proteins changes in intestinal epithelial cells.

Authors:  Huanlong Qin; Zhongwei Zhang; Xiaomin Hang; Yanqun Jiang
Journal:  BMC Microbiol       Date:  2009-03-31       Impact factor: 3.605

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.